8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 26, 2004

                             BSD MEDICAL CORPORATION
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                    0-10783                    75-1590407
- --------------------------------------------------------------------------------
(State or other jurisdiction        (Commission               (I.R.S. Employer
       of incorporation)            File Number)             Identification No.)

                 2188 West 2200 South
              Salt Lake City, Utah 84119
- --------------------------------------------------------------------------------
       (Address of principal executive offices)                  (Zip Code)

        Registrant's telephone number, including area code (801) 972-5555

                                       N/A
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13a-4(c))


Item 7.01. Regulation FD Disclosure.

BSD Medical Corporation issued a press release on October 26, 2004. A copy of
the press release is hereby furnished as Exhibit 99.1 attached hereto Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

Item 9.01. Financial Statements and Exhibits.

(c)   Exhibits

99.1  Press Release of BSD Medical Corporation dated October 26, 2004.


                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: October 26, 2004

                                          By: /s/  Hyrum A. Mead
                                              --------------------------
                                              President

EX-99.1

                                                                    Exhibit 99.1


             NYU Cancer Center Features New System by BSD Medical

    SALT LAKE CITY, Oct. 26 /PRNewswire-FirstCall/ -- BSD Medical Corp.
(OTC Bulletin Board: BSDM) today announced that New York University Clinical
Cancer Center has installed a new BSD-500 hyperthermia system produced by BSD
Medical, Corp.  The recently opened Center, which occupies 85,000 square feet
between Lexington and Third Avenues in New York City, includes several
multidisciplinary specialties for treatment of such cancers as breast and
other female cancers, digestive tract, prostate, brain, lung, blood, head and
neck, and skin (melanoma).  Many of these  cancers are applicable for
treatment with the BSD-500.
    BSD Medical expects more and more leading cancer treatment centers to
include hyperthermia therapy as an important component of their treatments for
cancer.  Clinical trials have shown a significant boost in both tumor control
and long-term survival when hyperthermia therapy is combined with radiation
therapy.  In phase III clinical trials where hyperthermia therapy was added to
ionizing radiation treatments, hyperthermia improved local relapse-free
survival for head and neck cancer from 24% to 68%, 2-year local control of
melanoma from 28% to 46%, complete response for recurrent breast cancer from
38% to 60%, 2-year survival for glioblastoma (brain cancer) from 15% to 31%
and 3-year survival for advanced cervical cancer from 27% to 51%, as compared
to the use of ionizing radiation therapy alone.
    NYU Clinical Cancer Center addresses a growing demand for comprehensive
outpatient care, with 85-90 percent of cancer patients treated in an
outpatient setting.  Dr. Silvia Formenti, Professor and Chairman of the
Department of Radiation Oncology at the NYU Medical Center, said, "The new
BSD-500 is ideal for outpatient environments.  Unlike earlier hyperthermia
systems, it is compact, portable and touch screen controlled, with both
treatment planning software and treatment monitoring conveniently provided in
the same system.  We currently have several patients undergoing superficial
hyperthermia treatment.  In addition, a new  research protocol for women who
suffer a breast recurrence after segmental mastectomy is undergoing
institutional approval.  It integrates hyperthermia with re-irradiation of
recurrent breast cancers after conservative breast treatment."  She continues:
"The recruitment to NYU of Gabor Jozsef, Ph.D., a colleague I collaborated
with when we were both at the University of Southern California, has been key
to assure the necessary physics expertise to finally build an Hyperthermia
Center in Manhattan".

    BSD Medical Corporation is the leading developer of microwave systems used
in thermal medicine for the treatment of cancer.  For more information about
BSD Medical Corp. or hyperthermia cancer therapy visit www.BSDMC.com.
Statements contained in this press release that are not historical facts are
forward looking statements, as that item is defined in the Private Securities
Litigation Reform Act of 1995.  All forward-looking statements, including
statements about the broad use of hyperthermia therapy in the treatment of
cancer are subject to risks and uncertainties, some of which are detailed in
part in the Company's filings with the Securities and Exchange Commission.


    Statements contained in this press release that are not historical facts
are forward looking statements, as that item is defined in the Private
Securities Litigation Reform Act of 1995.  All forward-looking statements,
including statements about the broad use of hyperthermia therapy in the
treatment of cancer are subject to risks and uncertainties, some of which are
detailed in part in the Company's filings with the Securities and Exchange
Commission.

SOURCE  BSD Medical Corporation
    -0-                             10/26/2004
    /CONTACT:  Hyrum A. Mead of BSD Medical Corporation, +1-801-972-5555, or
fax, +1-801-972-5930, investor@bsdmc.com/
    /Web site:  http://www.bsdmc.com/
    (BSDM)

CO:  BSD Medical Corporation; New York University Clinical Cancer Center
ST:  Utah, New York
IN:  HEA MTC EDU OTC
SU:  PDT